<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Immunostimulants; Rituximab: malignant diseases; Alemtuzumab; Ofatumumab" /><meta name="IX" content="Immunostimulants; Rituximab: malignant diseases; Alemtuzumab; Ofatumumab" /><title>8.2.3 Anti-lymphocyte monoclonal antibodies: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5649-anti-lymphocyte-monoclonal-antibodies.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5590-drugs-affecting-the-immune-response.htm">8.2 Drugs affecting the immune response</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5639-tacrolimus.htm" title="Previous: TACROLIMUS">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5658-alemtuzumab.htm" title="Next: ALEMTUZUMAB">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301034.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a310003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a398003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/18904-t.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Alemtuzumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: A &gt; Interactions of Alemtuzumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/24508-j.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Ofatumumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: O &gt; Interactions of Ofatumumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/17534-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Rituximab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: R &gt; Interactions of Rituximab</p></div></li></ul><ul><li><h3>British National Formulary (9)</h3></li><li><a href="PHP5658-alemtuzumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">ALEMTUZUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Anti-lymphocyte monoclonal antibodies</p></div></li><li><a href="PHP5659-mabcampath.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">MabCampath®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Anti-lymphocyte monoclonal antibodies &gt; ALEMTUZUMAB</p></div></li><li><a href="PHP5660-ofatumumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">OFATUMUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Anti-lymphocyte monoclonal antibodies</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22immunostimulants%22%22rituximab%22%22alemtuzumab%22%22ofatumumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (9)</a></li></ul><ul><li><h3>BNF for Children (5)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13856-rituximab-and-alemtuzumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">8.2.3 Rituximab and alemtuzumab</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13858-alemtuzumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">ALEMTUZUMAB</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Rituximab and alemtuzumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13859-mabcampath.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">MabCampath®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Rituximab and alemtuzumab &gt; ALEMTUZUMAB</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22immunostimulants%22%22rituximab%22%22alemtuzumab%22%22ofatumumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK1471.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; R</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/r06-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; R</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/18904-t.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/24508-j.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/17534-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/00228.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; A &gt; AL</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/10461.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; O &gt; OF</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/08239.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; R &gt; RI</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy (4)</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-A30.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; A</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-O6.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; O</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-R30.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; R</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22immunostimulants%22%22rituximab%22%22alemtuzumab%22%22ofatumumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>Stockley's Drug Interactions (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E6E3E0R0D1720.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Alemtuzumab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; A</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E2E3E0R0D923.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Rituximab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; R</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1><span>8.2.3 </span>Anti-lymphocyte monoclonal antibodies</h1><?highlighter on?><div id="pC" class="jN"><p id="PHP5650"><strong>Rituximab</strong> causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III–IV follicular non-Hodgkin's lymphoma and, in combination with other chemotherapy, for previously untreated stage III–IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see <a title="BNF:target-block: Rituximab NICE guidance (a)" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5652">NICE guidance</a> below). Rituximab is also licensed for maintenance therapy in patients with follicular non-Hodgkin's lymphoma that has responded to induction therapy (see <a title="BNF:target-block: Rituximab NICE guidance (c)" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5653">NICE guidance</a> below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin's lymphoma (see <a title="BNF:target-block: Rituximab NICE guidance (b)" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5654">NICE guidance</a> below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.</p><p>Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion. Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.</p><p id="PHP5651">Infusion-related side-effects (including cytokine release syndrome) are reported commonly with anti-lymphocyte monoclonal antibodies and occur predominantly during the first infusion; they include fever and chills, nausea and vomiting, allergic reactions (such as rash, pruritus, angioedema, bronchospasm and dyspnoea), flushing and tumour pain. Patients should be given paracetamol and an antihistamine before each dose of anti-lymphocyte monoclonal antibodies to reduce these effects. Premedication with a corticosteroid should also be considered. The infusion may have to be stopped temporarily and the infusion-related effects treated—consult product literature for appropriate management. Evidence of pulmonary infiltration and features of tumour lysis syndrome should be sought if infusion-related effects occur. </p><p>Fatalities following <strong>severe</strong> cytokine release syndrome (characterised by severe dyspnoea) and associated with features of tumour lysis syndrome have occurred after infusions of anti-lymphocyte monoclonal antibodies. Patients with a high tumour burden as well as those with pulmonary insufficiency or infiltration are at increased risk and should be monitored <strong>very closely</strong> (and a slower rate of infusion considered).</p><div id="PHP5652" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)</h3><p>Rituximab, in combination with:</p><ul><li><p>cyclophosphamide, vincristine and prednisolone (CVP);</p></li><li><p>cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP);</p> </li><li>  <p>mitoxantrone, chlorambucil and prednisolone (MCP);</p> </li><li>  <p>cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-alfa (CHVPi); <em>or</em></p></li><li>  <p>chlorambucil</p></li></ul><p>is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated patients.</p></div><div id="PHP5653" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (February 2008)</h3><p>Rituximab, in combination with chemotherapy, is an option for the induction of remission in patients with relapsed stage III or IV follicular non-Hodgkin's lymphoma.</p><p>Rituximab monotherapy as maintenance therapy is an option for the treatment of patients with relapsed stage III or IV follicular non-Hodgkin's lymphoma in remission induced with chemotherapy (with or without rituximab).</p><p>Rituximab monotherapy is an option for the treatment of patients with relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy). </p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (June 2011)</h3><p>Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non-Hodgkins's lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.</p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)</h3><p>Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia.</p></div><div id="PHP5654" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for aggressive non-Hodgkin's lymphoma (September 2003)</h3><p>Rituximab, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, is recommended for first-line treatment of CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV.</p><p>The use of rituximab for localised (stage I) disease should be limited to clinical trials.</p></div><p id="PHP5655"><strong>Alemtuzumab</strong> causes lysis of B and T lymphocytes and is licensed for use in patients with chronic lymphocytic leukaemia for whom fludarabine treatment is not appropriate. In common with rituximab, it causes infusion-related side-effects including cytokine release syndrome (see <a title="BNF:target-block: Anti-lymphocyte monoclonal antibodies and infusion-related side-effects" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5651">above</a>); premedication with paracetamol, an antihistamine, and a corticosteroid is recommended.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (August 2008) that alemtuzumab is accepted for restricted use within NHS Scotland for the treatment of B-cell chronic lymphocytic leukaemia (B-CLL) when fludarabine combination chemotherapy is not appropriate. Alemtuzumab is restricted to use in patients with previously untreated B-CLL, with the cytogenetic abnormality 17p-deletion.</p><p id="PHP5657"><strong>Ofatumumab</strong> causes lysis of B lymphocytes. It is licensed for treatment of chronic lymphocytic leukaemia in patients refractory to fludarabine and alemtuzumab. Infusion-related side-effects (including cytokine release syndrome—see <a title="BNF:target-block: Anti-lymphocyte monoclonal antibodies and infusion-related side-effects" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5651">above</a>) have been reported with ofatumumab; premedication with paracetamol, an antihistamine, and a corticosteroid is recommended.</p></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5658-alemtuzumab"><a href="PHP5658-alemtuzumab.htm" title="ALEMTUZUMAB">ALEMTUZUMAB</a></li><li id="_PHP5660-ofatumumab"><a href="PHP5660-ofatumumab.htm" title="OFATUMUMAB">OFATUMUMAB</a></li><li id="_PHP5662-rituximab"><a href="PHP5662-rituximab.htm" title="RITUXIMAB">RITUXIMAB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5639-tacrolimus.htm">Previous: TACROLIMUS</a> | <a class="top" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#">Top</a> | <a accesskey="]" href="PHP5658-alemtuzumab.htm">Next: ALEMTUZUMAB</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>